Journey Medical Corp. (DERM)

Over the past six months, Journey Medical Corp.'s stock price has declined. As of May 5, 2026, the share price was $5.18, a 20.31% decrease from $6.50 on May 6, 2025. The company's stock has fluctuated around earnings announcements, with a prior earnings date release showing an average move of -5.07%. Journey Medical Corporation announced its Q1 2026 financial results would be released on May 13, 2026, and reported its full-year 2025 financial results on March 25, 2026.

The skincare and dermatology market is influenced by seasonal changes, with consumer needs shifting with environmental factors. There may be increased demand for moisturizers in winter and for lightweight formulations and sun protection in summer. Analysts have referred to "stronger dermatology months" in their outlook for Journey Medical, suggesting an awareness of seasonal trends within the market.

Journey Medical Corp. is focused on developing and commercializing FDA-approved prescription pharmaceutical products for dermatological conditions. Its major products include Emrosi for rosacea, Qbrexza for excessive underarm sweating, Accutane for severe acne, Amzeeq for moderate to severe acne vulgaris, Zilxi for rosacea, Exelderm Cream and Solution for fungal skin infections, Targadox for severe acne, and Luxamend for wound healing.

Journey Medical Corp. is headquartered in Scottsdale, Arizona, and primarily markets its FDA-approved products within the United States. In 2023, the company expanded the reach of Qbrexza into additional territories in Asia through a licensing agreement with Maruho Co., Ltd.

Journey Medical Corp.'s brand reputation has been bolstered by the successful launch and rapid uptake of Emrosi, which has achieved strong prescription momentum and expanded payer access. However, the company has faced pressure on its Accutane franchise and other legacy products due to generic competition.

Journey Medical Corp. has a diverse ownership structure. Institutional shareholders hold 40.33% of the company, Journey Medical insiders own 30.90%, and retail investors account for 28.77%. Major institutional owners include Wasatch Advisors Inc., Tang Capital Management Llc, and Opaleye Management Inc. Key individual owners and insiders include Fortress Biotech Inc, Claude Maraoui, and Ramsey Alloush.